Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer
复制标题
DOI：
10.1056/nejmoa003013
复制
发表时间：
2001-12-06
影响因子：
158.5
通讯作者：
Crawford, ED
中科院分区：
文献类型：
--
作者：
Flanigan, RC;Salmon, SE;Crawford, ED
背景：肾切除术在转移性肾细胞癌中的价值一直存在争议。几个非随机研究表明，系统治疗的反应率较高，生存期较长的患者谁经历了nephrotectory.Methods：我们随机分配的转移性肾细胞癌患者谁是肾切除术的可接受的候选人进行根治性肾切除术后，用干扰素α-2b治疗或接受干扰素α-2b单独治疗。主要终点是生存，和次要终点是一个反应的肿瘤treatment.Results：中位生存的120个合格的患者分配到手术后，干扰素为11.1个月，和121个合格的患者分配到干扰素单独为8.1个月（P=0.05）。两组之间的中位生存期的差异是独立的性能状态，转移部位，并存在或不存在一个可测量的转移性lesion.Conclusions：肾切除术后，干扰素治疗的结果在较长的生存期转移性肾细胞癌患者比干扰素单独治疗。（N Engl J Med 2001;345：1655-9.）版权所有（C）2001马萨诸塞州医学会。
Background: The value of nephrectomy in metastatic renal-cell cancer has long been debated. Several nonrandomized studies suggest a higher rate of response to systemic therapy and longer survival in patients who have undergone nephrectomy.Methods: We randomly assigned patients with metastatic renal-cell cancer who were acceptable candidates for nephrectomy to undergo radical nephrectomy followed by therapy with interferon alfa-2b or to receive interferon alfa-2b therapy alone. The primary end point was survival, and the secondary end point was a response of the tumor to treatment.Results: The median survival of 120 eligible patients assigned to surgery followed by interferon was 11.1 months, and among the 121 eligible patients assigned to interferon alone it was 8.1 months (P=0.05). The difference in median survival between the two groups was independent of performance status, metastatic site, and the presence or absence of a measurable metastatic lesion.Conclusions: Nephrectomy followed by interferon therapy results in longer survival among patients with metastatic renal-cell cancer than does interferon therapy alone. (N Engl J Med 2001;345:1655-9.) Copyright (C) 2001 Massachusetts Medical Society.